alefacept (Amevive)

From Aaushi
Jump to navigation Jump to search

Indications

Contraindications

Dosage

  • 15 mg IM weekly

Adverse effects

Mechanism of action

Notes

  • Alefacept was withdrawn from the market in 2011 because of "business needs"

More general terms

References

  1. Prescriber's Letter 10(12):69 2003
  2. 2.0 2.1 2.2 FDA Medwatch http://www.fda.gov/medwatch/safety/2005/safety05.htm#Amevive
  3. 3.0 3.1 Physician's First Watch, September 23, 2013 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
    Rigby MR et al Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. The Lancet Diabetes & Endocrinology, September 23, 2013 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24622414 <Internet> http://www.thelancet.com/journals/landia/article/PIIS2213-8587(13)70111-6/abstract
    Herold KC Restoring immune balance in type 1 diabetes. The Lancet Diabetes & Endocrinology, September 23, 2013 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24622404 <Internet> http://www.thelancet.com/journals/landia/article/PIIS2213-8587%2813%2970123-2/fulltext
    Voluntary US Market Discontinuation of Amevive (alefacept) Astellas Pharma US, Inc. December 15, 2011 http://www.amevive.com/Physician%20letter.pdf